Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Silicon Genetics
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Masimo’s planned buyout of Lidco could help expand its footprint into the US.
Novartis has added an anti-osteoarthritic Nanobody, M6495, to its growing pipeline of candidates for the condition, in a €450m agreement with Merck KGaA that sees the latter deliver on its plans to find new homes for its osteoarthritis pipeline.
The COVID-19 pandemic has increased demand for products from all of Baxter’s businesses except its advanced surgery division. Overall, the diversified company’s global sales were up 8% in the first quarter.
- Other Names / Subsidiaries
- Agilent Technologies Inc.